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1007-179 Exercise Training Increases the Number of Endothelial 
Progenitor Cells in Patients With Coronary Heart 
Disease and Cardiovascular Risk Factors
Sabine Steiner, Alexander Niessner, Bernhard Richter, Sophie Ziegler, Martina Penka, 
Erich Minar, Christoph William Kopp, University of Vienna, Vienna, Austria, Austria
Background – Endothelial Progenitor Cells (EPCs) circulating in peripheral blood
defined by the surface antigens CD34, KDR and CD133 were shown to contribute to
neovascularization and rejuvinate arteries. Vascular function and cardiovascular risk
were inversely correlated with the number of EPCs. As regular physical exercise
improves endothelial dysfunction and promotes cardiovascular health we studied the
effect of exercise in patients with coronary heart disease and cardiovascular risk factors.
Methods - 15 patients with documented coronary heart disease and/or cardiovascular
risk factors joined a 12-week supervised endurance training. The number of circulating
EPCs was determined before and after the exercise period by whole blood flow cytome-
try.
Results – A significant increase in exercise frequency (pre 1.5±1.5 versus post 3.7±1.7
weekly training episodes; P<0.0001) and duration (pre 74±88min versus post 186±87min
weekly training time; P<0.0001) was observed in the study group (mean age±std;
52.9±10.1). The proportion of EPCs defined as CD34+/KDR+/CD133+-positive peripheral
blood mononuclear cells (BMCD34+/KDR+/CD133+; pre:0.7±0.8% versus post:2.7±2.2%;
P=0.006) as well as CD34+/KDR+-positive cells (BMCD34+/KDR+; pre:1.3±1.1% versus
post:3.3±2.6%; P=0.02) and CD34+/CD133+-positive (BMCD34+/CD133+; pre:45.5±14.8%
versus post:59.8±11.9%; P=0.01) significantly increased with exercise. In contrast, the
total number of CD34+-positive cells (BMCD34+) did not increase in response to exercise
training (pre:0.09±0.05% versus post: 0.09±0.05%; P=0.95).
Conclusions – Endurance training increases the number of EPCs in patients with CHD
and cardiovascular risk factors which may contribute to the atheroprotective effect attrib-
uted to regular physical activity.
1007-180 The Effect of Losartan Versus Atenolol on Circulating 
Adhesion Molecules in Essential Hypertension: A LIFE 
Substudy
Michael H. Olsen, Peter Clausen, Kristian Wachtell, Ulrik Andersen, Keld Neland, Hans 
Ibsen, Harriet Dige-Pedersen, Glostrup University Hospital, Copenhagen, Denmark, 
Rigshospitalet, Copenhagen, Denmark
Background: Hypertension and diabetes are associated with disturbances in circulating
adhesion molecules. We wanted to investigate a) the relation of adhesion molecules to
blood pressure and metabolic disturbances and b) the effect of a losartan vs. an atenolol
based antihypertensive regime on adhesion molecules.
Methods: In 43 LIFE patients with stage II-III hypertension and electrocardiographic left
ventricular hypertrophy we measured insulin sensitivity (M/IG) by a three-hour isoglyce-
mic hyperinsulinemic clamp, ambulatory 24-hour blood pressures (BP), plasma levels of
VCAM, ICAM, E-selectin and glucose and serum insulin and lipids after two weeks of pla-
cebo treatment and after one year of anti-hypertensive treatment with either an atenolol-
or a losartan-based regime reducing BP equally. Identical analyses were performed in 26
age and gender matched normotensive controls.
Results: At baseline VCAM, ICAM and E-selectin was not elevated in the patients as
compared to the controls. In patients, VCAM (r=0.39* and r=-0.24), ICAM (r=0.45** and
r=-0.34*) and E-selectin (r=0.41** and r=-0.39*) were related to serum insulin and M/IG,
but not to ambulatory or office BP or serum lipids. VCAM (484±127 mg/l to 448±97 mg/l*)
and ICAM (236±46 mg/l to 217±44 mg/l*) were reduced significantly without any differ-
ence between the two groups. E-selectin decreased insignificantly in patients receiving
losartan (64.5±34 mg/l to 50.7±19 mg/l) and the relative change was closely related to
the relative change in 24-hour systolic BP (r=0.88***) and in serum insulin (r=0.61*) in
patients receiving losartan. Although M/IG decreased in patients treated with atenolol as
compared to losartan we were not able to demonstrate any significant relationship
between changes in insulin sensitivity and concentrations of adhesion molecules.
*P<0.05,**P<0.01,***P<0.001.
Conclusion: Circulating VCAM and ICAM decreased during anti-hypertensive treatment
with losartan as well as atenolol based regimens. The decrements were independent of
concomitant changes in insulin resistance, although the levels of these circulating adhe-
sion molecules were related to insulin resistance rather than high BP at baseline.
1007-181 Oral Folic Acid Does Not Reduce Plasma 
Concentrations of the Endogenous Nitric Oxide 
Synthase Inhibitor Asymmetric Dimethylarginine in 
Hyperhomocysteinemic Subjects
Markus C. Stuehlinger, Bernhard Paulweber, Jan Schirnhofer, Otmar Pachinger, Olaf 
Stanger, University Clinic of Innsbruck, Innsbruck, Austria, Landeskrankenhaus 
Salzburg, Salzburg, Austria
Endothelial function is impaired in hyperhomocysteinemic subjects, however, the mecha-
nism for endothelial dysfunction in hyperhomocysteinemia remains unclear. We could
previously show that homocysteine (Hcy) inhibits NO production by accumulating asym-
metric dimethylarginine (ADMA), an inhibitor of NO synthase (NOS), in endothelial cells.
We also found that hyperhomocysteinemia after oral methionine leads to elevations of
ADMA in humans. Accordingly a randomized, placebo-controlled, double-blind study
design was chosen to investigate the effect of folic acid on Hcy and ADMA plasma con-
centrations.
29 hyperhomocysteinemic study subjects (16m/14f; 57±4y; Hcy>12µM) were random-
ized into 4 different groups: each individual was treated with either 0.4mg (n=7), 1mg
(n=7) or 5mg of folic acid (n=8), or placebo (n=7) for 8 weeks. Every 2 weeks blood was
drawn for measurements of Hcy and ADMA plasma concentrations. Additionally 5
healthy control subjects with normal Hcy concentrations were included to compare base-
line ADMA and Hcy values.
At baseline Hcy (13.36±0.40 vs. 6.91±1.27µM, p<0.001) as well as ADMA (1.67±0.86µM
vs. 0.55±0.03µM, p<0.001) plasma concentrations were significantly higher in hyperho-
mocysteinemic subjects. All doses of oral folate significantly reduced Hcy plasma con-
centration after 8 weeks of treatment: with 5mg from 13.08±0.57 to 10.30±0.95
(p=0.009), with 1mg from 12.63±0.79 to 9.88±1.45; (p=0.07) and with 0.4mg of folate
from 13.94±0.75 to 10.28±0.73 (p=0.001), whereas placebo did not affect plasma Hcy
(from 14.40±1.01 to 14.38±0.59; p=n.s.). ADMA plasma concentrations however were
not affected by placebo (from 1.66±0.19 to 1.61±0.17; p=n.s.) or folate at any dose: with
5mg from 1.59±0.10 to 1.77±0.16, with 1mg from 1.86±0.21 to 1.98±0.30 and with 0.4mg
from 1.58±0.22 to 1.56±0.20 (all p=n.s.).
In this randomized, placebo-controlled, double-blind trial oral folate caused significant
reductions of plasma Hcy within 8 weeks of treatment. The decline of Hcy however was
not accompanied with decrements of plasma ADMA concentrations. Our results suggest
that the beneficial effects of folate on endothelial function and the NOS pathway are not
mediated by ADMA.
1007-182 Aldosterone and Plasma Renin Activity Influence 
Plasma Plasminogen Activato Inhibitor-1 Levels in 
Overweight Subjects
James A. S Muldowney, III, Barbara C. Roberts, Joseph W. Covington, John A. 
Schoenhard, Nancy J. Brown, Douglas E. Vaughan, Vanderbilt University Medical 
Center, Nashville, TN
Plasminogen activator inhibitor-1 (PAI-1) is an important predictor of mortality in myocar-
dial infarction, and serves as a key regulator of the fibrinolytic system. We have previ-
ously shown that plasma PAI-1 correlates with body mass index (BMI), plasma renin
activity (PRA), and aldosterone levels in hypertensive subjects. In order to better under-
stand the relationship between PAI-1 and these associated factors, we investigated a
more diverse population of subjects. In the present study, 54 subjects were studied, (33%
Male, 37% African-American, 56% hypertensive, 82% overweight or obese, mean age 49
± 8). Height, weight, blood-pressure, plasma renin activity, aldosterone and PAI-1 were
measured. The mean blood pressure of our population was 135/88 ± 15/12 mmHg, BMI
30 ± 5 kg/m2, PRA 0.85 ± 0.65 ng AngI/ml/hr, plasma aldosterone 6.0 ± 3.4 pg/dl, and
plasma PAI-1 18 ± 17 ng/ml. While BMI correlated with plasma PAI-1 in the composite
group, BMI is a particularly strong predictor of plasma PAI-1 levels in low renin subjects
(R = 0.676, P = 0.002). This correlation did not hold true in subjects with a PRA >/= 0.5.
In addition, in overweight and obese subjects (BMI >/= 25), there is a correlation between
plasma aldosterone and PAI-1 levels (R = 0.376, P = 0.012), but not in lean subjects. This
relationship was gender-specific, with a strong correlation between aldosterone and PAI-
1 in men(R = 0.602, P = 0.008), but not women (R = –0.001, P = 0.993). We conclude
that BMI predicts PAI-1 in low renin individuals. Plasma aldosterone levels also correlate
with PAI-1 levels in men and overweight individuals. Although BMI is widely recognized
as a strong predictor of plasma PAI-1, clearly this relationship is influenced and con-
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1008-183 Effects of Ezetimibe, Simvastatin, and Ezetimibe-
Simvastatin on Noncholesterol Sterol
Gerd Assmann, Frank Kannenberg, Wayne Weng, John Erbey, Ani John, Diane Tribble, 
Thomas Musliner, Leslie J. Lipka, Enrico P. Veltri, University of Munster, Munster, 
Germany, Merck/Schering-Plough, North Wales, PA
Background: Emerging interest in elevated phytosterols as a potential risk marker for
coronary artery disease (CAD) is based on clinical findings in patients with hereditary
lipid storage disorders (e.g. sitosterolemia) and observational studies in cohorts of CAD
patients.
Methods: A post-hoc analysis of a randomized, double-blind, placebo-controlled trial of
primary hypercholesterolemia patients (LDL-C 145-250 mg/dl and TG <350 mg/dl) was
conducted to examine the effects of 12 weeks of daily treatment with ezetimibe (EZE) 10
mg, simvastatin (Simva) pooled doses 10-80 mg, or ezetimibe 10 mg/simvastatin pooled
doses 10-80 mg (EZE/Simva) coadministration on concentrations of phytosterols (sito-
sterol and campesterol) and cholesterol precursors (lathosterol and desmosterol). Base-
line and endpoint plasma samples of 578 patients were analyzed by GC-mass
spectrometry.
Results: 
EZE significantly lowered concentrations of phytosterols and increased the cholesterol 
precursor-lathosterol. Simva significantly lowered concentrations of cholesterol 
precursors but did not affect phytosterol concentrations. EZE/Simva coadministration 
lowered both concentrations of phytosterols and cholesterol precursors. Results for the 
sterol:cholesterol ratios were similar to those for concentrations, except that Simva 
increased ratios of phytosterol:cholesterol ratios
